Drilldown: Medicines
Use the filters below to narrow your results.
generic:
4-AcO-DET (1) ·
4-AcO-DiPT (1) ·
4-AcO-DMT (1) ·
4-AcO-MET (1) ·
4-AcO-MiPT (1) ·
4-HO-DET (1) ·
4-HO-DiPT (1) ·
4-HO-DPT (1) ·
4-HO-EPT (1) ·
4-HO-MET (1) ·
4-HO-MiPT (1) ·
5,6-MDO-DMT (1) ·
5-MeO-DALT (1) ·
5-MeO-DiPT (1) ·
5-MeO-DMT (1) ·
5-MeO-MiPT (1) ·
aMT (1) ·
Apixaban (1) ·
Baeocystin (1) ·
Bufotenin (1) ·
DET (1) ·
DiPT (1) ·
DPT (1) ·
EPT (1) ·
MET (1) ·
MiPT (1) ·
Psilocin (1) ·
Rivaroxaban (1) ·
Warfarin (1)
brand:
classes: (Click arrow to add another value)
mechanism:
None (1) ·
5-HT2A agonist (15) ·
5-HT2A agonist; 5-HT3 antagonist (1) ·
5-HT2A agonist; minor psilocybin mushroom alkaloid (1) ·
5-HT2A agonist; primarily auditory effects (1) ·
5-HT2A agonist; sigma-1 agonist (1) ·
Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) ·
Potent 5-HT2A agonist; sigma-1 agonist (1) ·
Prodrug of 4-HO-DET; 5-HT2A agonist (1) ·
Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) ·
Prodrug of 4-HO-MET; 5-HT2A agonist (1) ·
Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) ·
Prodrug of psilocin; 5-HT2A agonist (1) ·
'"`UNIQ--vote-000001F6-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-000001F7-QINU`"'. (1) ·
'"`UNIQ--vote-0000050D-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-0000050E-QINU`"'. (1)
uses:
None (26) ·
'"`UNIQ--vote-000001F8-QINU`"', '"`UNIQ--vote-000001F9-QINU`"', '"`UNIQ--vote-000001FA-QINU`"' (1) ·
'"`UNIQ--vote-0000050F-QINU`"', '"`UNIQ--vote-00000510-QINU`"', '"`UNIQ--vote-00000511-QINU`"', '"`UNIQ--vote-00000512-QINU`"' (1) ·
'"`UNIQ--vote-00000700-QINU`"', '"`UNIQ--vote-00000701-QINU`"', '"`UNIQ--vote-00000702-QINU`"', '"`UNIQ--vote-00000703-QINU`"', '"`UNIQ--vote-00000704-QINU`"' (1)
starting dose:
None (26) ·
NVAF: 20 mg PO once daily with the evening meal (15 mg if CrCl 15-50); acute VTE: 15 mg BID for 21 days, then 20 mg daily; CAD/PAD: 2.5 mg BID with aspirin (1) ·
NVAF: 5 mg PO BID (2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL); acute VTE: 10 mg BID for 7 days, then 5 mg BID (1) ·
Typical 5 mg PO daily; 2.5 mg in elderly, low body weight, malnutrition, hepatic dysfunction. Genotype-guided initial dosing per CPIC/IWPC algorithms (CYP2C9, VKORC1, CYP4F2) is one of the most-established PGx applications in current practice (1)
preparations:
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
None (26) ·
~100% (oral)'"`UNIQ--ref-00000706-QINU`"' (1) ·
~50% (oral; not significantly affected by food)'"`UNIQ--ref-000001FC-QINU`"' (1) ·
~80-100% with food at 15-20 mg doses (10 mg dose: ~80% without food); '''must be taken with food''' at therapeutic doses'"`UNIQ--ref-00000514-QINU`"' (1)
pregnancy:
Showing below up to 29 results in range #1 to #29.